Drug Profile
Research programme: biologic agents - Kuhnil Pharmaceutical Company
Alternative Names: KI-0801; KI-0901Latest Information Update: 07 Oct 2021
Price :
$50
*
At a glance
- Originator Kuhnil Pharmaceutical Company
- Class Antibodies; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Neurological disorders
Most Recent Events
- 07 Oct 2021 Discontinued for Neurological disorders in South Korea (unspecified route) (Kuhnil Pharma pipeline)
- 28 Aug 2018 No recent reports of development identified for research development in Neurological-disorders in South Korea
- 09 Aug 2016 KI 0801 is still in research stage for Neurological disorders in South Korea